Summary
Strategy paper on new clinical indications based on i) improved diagnostics and availability of stem cells for gene editing (rare diseases), ii) new immunotherapeutic options, iii) tissue regeneration vs. tissue replacement approaches
More information & hyperlinks
Search
Organisations
- Not specified